HIF1A and acute myeloid leukemia: It was reported that AML cells displayed less vulnerability to adriamycin (ADR) in the presence of hypoxia, while blocking hypoxia-inducible factor 1α (HIF-1α) via CdCl2 can render AML cells again susceptible to ADR, even under hypoxia [189].